Today the BIA launched the next phase of its Celebrating UK Bioscience campaign. The aim of this campaign is to showcase the great work taking place in the sector – focusing on the potential human benefits of treatments that are currently in research and development – and to bring a greater understanding of the UK biotechnology sector to new audiences.
Biotechnology is technology based on biology, the science of life. Scientists in our sector work with living organisms to drive the development and manufacture of drug treatments, advanced therapies and diagnostic tests to support patients in the UK and beyond. The BIA is the trade association for innovative healthcare companies rooted in the UK’s bioscience base. The sector continues to evolve, investing in research and development activities, and translating research from the UK’s world leading science base into medicines to treat patients.
There is great depth and breadth in UK biotechnology: from a strong and emerging regenerative medicine and cell therapy sector, to specialist biomanufacturing companies developing therapies for cancer treatment, to personalised treatments and new antimicrobials. Advances in technologies such as synthetic biology are impacting upon the development of new types of therapeutics and new production methods. UK bioscience is not only changing lives, but saving them. It is vital that the sector continues to get the support it needs to keep this essential research and development going, now and in the future.
This campaign takes a look behind the scenes in the labs of some of our members to see what they are researching and developing and what the possible patient benefits these drugs and treatments could have in the future. The report is divided into five treatment areas: cancer, antimicrobial resistance, type one diabetes, dementia and Duchenne muscular dystrophy. Most people will be familiar with cancer and dementia, but this project wanted to look at less understood areas such as type one diabetes and antimicrobial resistance, as well as a rare disease, Duchenne muscular dystrophy, to demonstrate the breadth of scientific research and development taking place in our sector.
A number of charities that took part in this project are directly funding research in BIA member companies. Collaborations between industry and medical research charities are increasingly recognised as a mutually beneficial relationship. This brings the patient perspective to companies and enables patients to access clinical trials or to stay informed about R&D, and even allows vital funds to be channelled into clinical research.
Alongside the report, there is a series of infographics and videos, which add further insight into each condition and what BIA members are doing to tackle them. You will hear first-hand from patients and their families who have shared their personal stories and what they hope UK biotech will be able to achieve. Go to www.bioindustry.org/newsandresources/celebrate to view and download all the resources.